Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma

Secondary malignancies due to alkylating agents or topoisomerase II inhibitors are a concern in patients treated for primary brain tumors of the nervous system. Myelosuppression is the dose-limiting toxic effect of the alkylating agent temozolomide; reversible hematologic toxicity consisting mainly...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Clark, Stephen W., Taylor, Jennie, Wang, Daphne L., Abramson, Jeremy S., Batchelor, Tracy T.
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2013
Témata:
Clinical/Scientific Notes
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3770207/
https://ncbi.nlm.nih.gov/pubmed/23685934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e318297eea6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky